Artwork

Content provided by Limelight Alpha. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Limelight Alpha or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Talking Stocks: The Pros and Cons Every Investor Ought to Know About Gene Editing

53:06
 
Share
 

Manage episode 313224437 series 3262794
Content provided by Limelight Alpha. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Limelight Alpha or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Editing genes to fix genetic mutations could revolutionize how we treat disease, but gene editing research is only in early stages, and plenty still needs to learned before we know it's safe for widespread use.

In this episode of Limelight Alpha's Talking Stocks, 7Investing Lead Advisor, Maxx Chatsko, joins Todd Campbell to explains the pros and cons of gene editing. The duo discuss:

  • How gene editing, including CRISPR Cas, compares to RNAi therapies;
  • What gene editing companies are furthest along in their research;
  • What data is on tap from leading gene editing stocks, including Crispr Therapeutics, Editas Medicine, Caribou Biosciences, and Intellia Therapeutics, and
  • What could go wrong in gene editing drug development, including risks associated with double-strand breaks.

You can learn more about 7Investing here: https://7investing.com/subscribe/?referred_by_id=747

You can learn more about Limelight Alpha here: https://seekingalpha.com/author/limelight-alpha-management-partners/research

Follow Limelight Alpha on Twitter: @AlphaLimelight

Follow Maxx Chatsko on Twitter: @7MaxxChatsko

--- Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

  continue reading

67 episodes

Artwork
iconShare
 
Manage episode 313224437 series 3262794
Content provided by Limelight Alpha. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Limelight Alpha or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Editing genes to fix genetic mutations could revolutionize how we treat disease, but gene editing research is only in early stages, and plenty still needs to learned before we know it's safe for widespread use.

In this episode of Limelight Alpha's Talking Stocks, 7Investing Lead Advisor, Maxx Chatsko, joins Todd Campbell to explains the pros and cons of gene editing. The duo discuss:

  • How gene editing, including CRISPR Cas, compares to RNAi therapies;
  • What gene editing companies are furthest along in their research;
  • What data is on tap from leading gene editing stocks, including Crispr Therapeutics, Editas Medicine, Caribou Biosciences, and Intellia Therapeutics, and
  • What could go wrong in gene editing drug development, including risks associated with double-strand breaks.

You can learn more about 7Investing here: https://7investing.com/subscribe/?referred_by_id=747

You can learn more about Limelight Alpha here: https://seekingalpha.com/author/limelight-alpha-management-partners/research

Follow Limelight Alpha on Twitter: @AlphaLimelight

Follow Maxx Chatsko on Twitter: @7MaxxChatsko

--- Support this podcast: https://podcasters.spotify.com/pod/show/limelight-alpha/support

  continue reading

67 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide